Eikon Therapeutics | LinkedIn (original) (raw)
``
Biotechnology Research
Hayward, CA 21,114 followers
Pioneering a new method of drug discovery based on tracking and measuring movement of individual proteins in live cells
About us
Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Industry
Biotechnology Research
Company size
201-500 employees
Headquarters
Hayward, CA
Type
Privately Held
Founded
2019
Locations
Employees at Eikon Therapeutics
Updates
- Our team at Eikon Therapeutics is making waves in drug discovery by leveraging cutting-edge AI technologies. Eikon Associate Director Adi Hanuka, PhD, recently presented how our advanced AI models are overcoming challenges in predicting drug absorption. By integrating public and proprietary data, our models are significantly improving prediction accuracy, leading to faster and more effective drug development. Excited about the future? We are too! Stay tuned for more groundbreaking advancements from our talented team.#TeamEikon #AI #DrugDiscovery #BiotechInnovation
Associate Director @EikonTX | Physics<>ML | Ex-SLAC/Stanford | Forbes 30 Under 30
5d Edited
In drug development, accurately predicting drug properties is crucial. But how do you achieve this with limited proprietary data? At Eikon Therapeutics we found a solution that worked well for us. 🚀💊 In this article, we describe our methods to improve our AI models for predicting drug properties and their impact on our drug discovery process.
Bridging the Data Gap: How Eikon Therapeutics is Enhancing Drug Discovery with AI Adi Hanuka, PhD on LinkedIn -
21,114 followers
1w Edited
At Eikon Therapeutics, our Clinical team plays a vital role in translating groundbreaking discoveries into life-changing medicines for patients with unmet needs, including cancer and neurodegenerative diseases. With a commitment to patient-centered clinical excellence, we prioritize the well-being of participants in our clinical trials and strive to deliver high-quality data that supports the development of effective therapies. Our track record showcases our integrated capabilities to advance both in-licensed assets and those emerging from our proprietary platform. As part of #TeamEikon, you'll contribute to a vision that redefines the boundaries of science, driving innovation that has the potential to transform the lives of patients around the world. Explore West- and East-Coast opportunities to join our clinical team here: https://lnkd.in/g7V6b9RZ #ClinicalResearch #HealthcareInnovation #ScienceCareers - Navigating the complexities of clinical trial supply chains is more challenging than ever as the industry adapts to new technologies and ever-changing global regulations. On September 17, Eikon Therapeutics’ Senior Director of Clinical Supply Chain Reid Tonik will share insights on “Creating a Clinical Supply Chain Playbook for Onboarding Acquired Assets” at Clinical Trial Supply West Coast in San Francisco. Reid will cover best practices and actionable strategies including: ➡ Identifying priorities and guiding transition activities while mitigating risks to patient dosing and trial continuity in a culturally and personally mindful way. ➡ Deciding when and what to integrate, and assessing the impact on the acquired portfolio. ➡ Tools of the trade and lessons learned from past mistakes. We hope to see you there #ClinicalTrials #ClinicalOperations #CTSWestCoast
- We’re so proud of #TeamEikon for how they support and give back to our communities! Eikon’s Veterans Employee Resource Group (ERG) includes 11 veterans, military spouses, and military supporters. This recent partnership with Operation Homefront is the first of many events planned in the coming months where the group will be volunteering and showing support for our local military community.
HR Operations Specialist 2
1mo
I’m thrilled to announce that the Eikon Therapeutics Veteran Employee Resource Group (ERG) recently partnered with Operation Homefront for a successful back-to-school brigade. Thanks to the generous contributions from Eikon employees and Eikon’s matching program, we raised $2,340 to support 300 military children at Travis Air Force Base, CA, with essential school supplies. This initiative eased the financial burden for military families during the costly back-to-school season and set these kids up for a great academic year. Eikon’s Veteran ERG is proud to have positively impacted our local military community and grateful for everyone who participated in this meaningful cause. I want to give a special shoutout to Amanda Hollowell, an Eikon Veteran ERG member and Military Spouse, for coordinating this event. BRAVO-ZULU! #eikontherapeutics #operationhomefront - We’re looking forward to the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 4th in New York City. Eikon Therapeutics’ CEO Roger M. Perlmutter and CFO Alfred (Freddie) Bowie will present a business update on the company’s progress including recent advancements in the company’s pipeline and clinical development programs, as well as updates related to our Eikon Systems business. To access the archived recording after the event, visit the link in comments.
- "I’m excited about the prospect that new technological advances have afforded us to further accelerate innovative therapeutic development.” Ten years after playing an instrumental role in bringing Keytruda —one of the most impactful cancer therapies in history— to market, Roy Baynes, MD, PhD, now serves as Eikon Therapeutics' Chief Medical Officer. At Eikon, Roy is building one of the industry's most sophisticated clinical organizations and a therapeutic pipeline with the potential to deliver important new medicines to address serious illnesses that reflect areas of unmet medical need. In a recent podcast interview, Roy shared insights from his accomplished career and discussed what excites him most about the future of medicine, particularly the potential of new technologies and artificial intelligence. Catch the full interview and explore current opportunities to join Roy's growing clinical team at Eikon (links in comments).#TeamEikon #Biotech
-
21,114 followers
4mo Edited
If you’re keen to learn more about Eikon's progress over recent months, check us out at ASCO (and link below), follow on LinkedIn or leave a comment.#eikontx #science #engineering #therapeutics
Excited to connect with colleagues, collaborators, and the clinical oncology community at #ASCO24! #TeamEikon will be sharing updates from our EIK1001 and EIK1003 programs and hosting meetings at Exhibit Hall Booth 32116. Swing by and say hi! Discover more about our abstracts: https://lnkd.in/g2DP-vpu - Excited to connect with colleagues, collaborators, and the clinical oncology community at #ASCO24! #TeamEikon will be sharing updates from our EIK1001 and EIK1003 programs and hosting meetings at Exhibit Hall Booth 32116. Swing by and say hi! Discover more about our abstracts: https://lnkd.in/g2DP-vpu
Join now to see what you are missing
Similar pages
- Arcus Biosciences Biotechnology Hayward, California
- Allogene Therapeutics Biotechnology South San Francisco, California
- Denali Therapeutics Biotechnology Research South San Francisco, California
- Arsenal Biosciences, Inc. Biotechnology Research South San Francisco , CA
- Maze Therapeutics Biotechnology Research South San Francisco, California
- Scorpion Therapeutics Biotechnology Research
- Sana Biotechnology, Inc. Biotechnology Research Seattle, Washington
- Beam Therapeutics Biotechnology Research Cambridge, Massachusetts
- Caribou Biosciences Biotechnology Research Berkeley, CA
- Vertex Pharmaceuticals Biotechnology Research Boston, MA
Browse jobs
- Scientist jobs 59,545 open jobs
- Director jobs 1,374,979 open jobs
- Engineer jobs 608,159 open jobs
- Clinical Specialist jobs 31,202 open jobs
- Senior Manager jobs 230,444 open jobs
- Vice President jobs 243,153 open jobs
- Associate Scientist jobs 22,764 open jobs
- Principal Scientist jobs 15,154 open jobs
- Corporate Development Specialist jobs 1,350 open jobs
- Manager jobs 2,003,890 open jobs
- Chemist jobs 48,925 open jobs
- Senior Scientist jobs 21,931 open jobs
- President jobs 91,996 open jobs
- Analyst jobs 760,055 open jobs
- Organic Chemist jobs 4,409 open jobs
- Project Manager jobs 312,603 open jobs
- Data Analyst jobs 550,881 open jobs
- Recruiter jobs 321,337 open jobs
- Senior jobs 1,142,468 open jobs
- Head jobs 1,135,865 open jobs